Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
A pragmatic approach to heart screening is to use the cheap, non-invasive Calcium CT (CAC) scan as a first-line filter. If the result is zero, further testing may be unnecessary. A non-zero score, indicating a propensity to build plaque, then justifies the more invasive and expensive ($2,000+) angiogram to assess soft plaques and blockage levels. This tiered strategy makes advanced screening accessible and cost-effective.
Related Insights
Dr. Sara Gottfried strongly recommends a Coronary Artery Calcium (CAC) score, a CT scan of the chest, for all women by age 45. This simple, self-orderable test provides a critical assessment of cardiometabolic health, enabling early, personalized intervention for heart disease risk.
Top preventative cardiologists privately advise their own families to get a CAC scan at age 30-35. If the score is non-zero, they prescribe statins to get LDL cholesterol below 40—less than half the standard 'green zone' level. This reveals a significant gap between public guidelines and the aggressive preventative strategies used by experts for their loved ones.
Highly athletic individuals can inadvertently train their hearts to compensate for underlying disease, causing them to pass stress tests and EKGs while still at high risk. This was the case for Dave Goldberg, who passed a running EKG five months before dying from undiagnosed heart disease. It highlights a critical flaw in relying on performance-based tests for cardiac screening in fit populations.
Decades ago, a legislative battle pitted preventative technology (calcium CT scanners) against treatment solutions (stents). The stent lobby won, shaping medical standards to favor profitable, reactive procedures over inexpensive, proactive screening. This regulatory capture explains why cholesterol remains the primary marker despite its flaws, hindering widespread adoption of more effective preventative tools.
Individual early-detection tests like blood biopsies or MRIs are imperfect, leading to false positives and negatives. The next step in diagnostics is a "multimodal" approach, layering different screening types, such as genomic blood tests and imaging, to create a more accurate and comprehensive picture of a patient's health.
Standard cholesterol tests are poor predictors of heart attacks, as 50% of victims fall within the 'normal' range. This reliance on an incomplete metric means millions of people, including those with healthy lifestyles, may have a false sense of security about their heart health, overlooking the more definitive presence of arterial plaque.
Relying on blood lipid panels (LDL, etc.) to assess cardiovascular risk is misleading, as they don't confirm arterial plaque. A CT angiography (CCTA), like a Cleerly scan, provides direct imaging of both hard and soft plaque, offering a far more accurate assessment of actual heart disease risk.
The current healthcare model is backwards. It's more cost-effective to proactively get comprehensive diagnostics like blood work done twice a year than to rely on multiple, expensive doctor visits after symptoms appear. This preventative approach catches diseases earlier and reduces overall system costs.
The blood test is a first-line screen to identify patients who may need more invasive and expensive follow-ups like PET scans or CSF tests. This minimizes unnecessary procedures for those at low risk, optimizing the diagnostic pathway and improving patient experience.
The test's primary purpose is not to replace definitive diagnostics like mammograms but to act as a scalable, low-cost pre-screening tool. In low-resource settings, it can stratify a large population, identifying a high-risk group that can then be targeted with more expensive and resource-intensive screening methods, improving efficiency.
